Montreal, April 3, 2024
Report highlights:
- 6,4% increase in total samples (including urine, non-Athlete Biological Passport [ABP] blood and dried blood spot [DBS] samples) analyzed and recorded in ADAMS in 2022 (256) compared to 770 (2021 241).
- Increase in total percentage of Adverse Analytical Findings (AAR) from year to year.
- Increase in total number of samples analyzed and reported by most WADA-accredited laboratories and WADA-approved laboratories in ADAMS in 2022 compared to 2021.
- Increase in total number and percentage of non-PBA and DBS blood samples analyzed in 2022.
- 1,4% increase in number of PBA-related blood samples analyzed in 2022.
- Increase in total RAA and percent RAA for EPO receptor antagonists (including erythropoietin [EPO] and other EPO receptor agonists), growth hormone releasing factors (GHRFs), and GC/C/IRMS testing in 2022.
The World Anti-Doping Agency (WADA) today released its 2022 Doping Control Data Report [available only in English], which summarizes the results of all samples analyzed by WADA-accredited laboratories analyzed and reported in the Anti-doping administration and management system (ADAMS) of the AMA in 2022.
The 2022 Report – which includes a Executive summary [in English] and sub-reports by laboratory, sport, control authority, as well as for blood tests of the Athlete's biological passport (PBA) – presents analysis data for in-competition and out-of-competition urine samples, blood samples collected or not as part of the PBA, as well as adverse analytical findings (AAR) and atypical results .
“The WADA Annual Testing Data Report is the most comprehensive overview of all doping control samples analyzed and reported by WADA-accredited and approved laboratories worldwide,” said the Director General. of the AMA, Olivier Niggli. WADA is pleased to see that the number of doping tests in the testing data continues to increase in all areas and that these are approaching the results obtained before the pandemic (2019). An intelligence-driven strategic plan for in-competition and out-of-competition testing is an important part of any strong anti-doping program and it is not the only angle of attack. Implemented alongside values-based education, intelligence and investigation, and other strategies, testing is an important method of detection and deterrence that helps protect athletes and keep sport clean.
“The Doping Control Data Report is an important tool for collaboration between anti-doping organizations. The important data and information contained in the report provides anti-doping organizations with a key resource for evaluating strategy and identifying potential trends, best practices and areas for improvement. Anti-doping organizations are able to use the valuable information contained in the report to tailor their anti-doping programs and ensure they are effective, intelligent and based on solid data. »
To facilitate the interpretation of the 2022 Report, a complete “questions and answers” document [in English] is available in the Related Documents section of the page 2022 Doping Control Data Report. It is particularly important to note that:
- An isolated result does not necessarily correspond to a single athlete. The data may correspond to multiple results concerning or taken from the same athlete, for example in the case of longitudinal studies of testosterone.
- The number of AARs shown in the report does not necessarily correspond to the number of Anti-Doping Rule Violations (ADRVs) reported by Anti-Doping Organizations (ADOs). Indeed, all results are subject to a results management process led by ADOs, which includes matching results with Therapeutic Use Exemptions (TUEs) and longitudinal studies that can provide result in no response or no sanction.
- Testing figures are typically released more than a year later to allow sufficient time to collect and collate the significant amount of data included in the report.
- As usual, this report does not provide statistics on ADRVs, which are the subject of a separate report. The 2021 VRAD Report will be finalized and published soon. The VRAD Report provides information on decisions arising from analytical and non-analytical cases at the end of results management – a process which can be lengthy, taking into account, among other things, possible investigations and appeals.
